PATENT CLAIM ANALYSIS

Application Number: 15752896
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "210180"]

Abstract:
Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

Claim (Index 2):
The substituted quinolone derivative, or a pharmaceutically acceptable salt or a stereoisomer thereof according to  claim 1 , characterized in: when the R 1 , R 2  and ring A constitute a fused 5- to 6-membered substituted heterocyclic ring, the fused 5- to 6-membered substituted heterocyclic ring has one of the following structures: wherein, X is CH 2  or N; R 11  is optionally selected from: hydrogen, halogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy or isopropoxy; R 12  and R 13  are the same or different and are optionally selected from: hydrogen, halogen, \u2014(CR 15 R 16 ) O R 14 , \u2014O(CR 15 R 16 ) O R 14 , \u2014(CR 17 \u2550CR 18 ) p R 14 , \u2014O(CR 17 \u2550CR 18 ) p R 14 , wherein, o, p, and q=0-6, and R 14 , R 15 , R 16 , R 17 , and R 18  are the same or different and are optionally selected from: \u2014H, \u2014F, \u2014Cl, \u2014Br, \u2014I, \u2014CF 3 , \u2014OCF 3 , \u2014OH, \u2014COOH, \u2014COOCH 3 , \u2014COOC 2 H 5 , \u2014COOC 3 H 7 , \u2014COOCH(CH 3 ) 2 , \u2014COOC(CH 3 ) 3 , \u2014(C\u2550O)\u2014NR 19 R 20 , \u2014SO m \u2014NR 19 R 20 , \u2014CHR 19 R 20 , \u2014OR 19  or \u2014NR 19 R 20 ; m=1-2; R 19  and R 20  are the same or different and are optionally selected from: hydrogen, halogen, or C 1 -C 6  alkyl; or, R 19  and R 20  constitute a saturated or an unsaturated 5- to 8-membered heterocyclic group; or, R 12  and R 13  constitute a substituted or an unsubstituted C 5 -C 18  aliphatic cycloalkyl which contains 1-4 heteroatoms.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 88.0
- Lexical Diversity: 1.88235
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14411515', '14207868', '13928696', '13294303', '14916177']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8305682342472593
- 35 USC 102 Novelty (BERT): 0.5599068859730577
- Combined Prediction Score: 0.8035020994198392
- Mean Citation Score: 423.024436
- Max Citation Score: 440.52917
- Similarity Product: 354.0638363702595

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test